# Vyome Holdings Inc. (HIND) Source: https://www.quantisnow.com/company/HIND Generated: 2026-11-11T02:37:02.618Z - Ticker: HIND - Exchange: NASDAQ - Sector: Health Care - Industry: Biotechnology: Pharmaceutical Preparations - IPO year: 2016 - SEC CIK: 0001427570 ## Latest HIND news and filings - 2026-10-26 12:00 UTC [Vyome Co-Founder Dr. Shiladitya Sengupta Promoted to Professor at Harvard Medical School](https://www.quantisnow.com/insight/vyome-co-founder-dr-shiladitya-sengupta-promoted-to-professor-at-harvard-6757059) - 2026-09-14 12:00 UTC [Leadership Update] [Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer](https://www.quantisnow.com/insight/vyome-appoints-experienced-public-company-finance-executive-jerry-leonard-as-6713780) - 2026-09-03 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Vyome Holdings Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-vyome-holdings-inc-6705398) - 2026-09-03 12:04 UTC [Analyst Coverage Initiated] [Chardan Capital Markets initiated coverage on Vyome Holdings with a new price target](https://www.quantisnow.com/insight/chardan-capital-markets-initiated-coverage-on-vyome-holdings-with-a-6704346) - 2026-09-01 21:00 UTC [SEC Form 3] [SEC Form 3 filed by new insider Leonard Jerry](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-leonard-jerry-6701721) - 2026-08-28 20:31 UTC [SEC Form 8-K] [Vyome Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/vyome-holdings-inc-filed-sec-form-8-k-leadership-update-financial-6698531) - 2026-08-25 20:05 UTC [SEC Form 8-K] [Vyome Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/vyome-holdings-inc-filed-sec-form-8-k-results-of-operations-6694184) - 2026-08-25 12:00 UTC [Earnings] [Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet](https://www.quantisnow.com/insight/vyome-holdings-reports-second-quarter-2026-results-highlighted-by-advancement-6693630) - 2026-08-12 20:32 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Vyome Holdings Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-vyome-holdings-inc-6678236) - 2026-07-01 12:00 UTC [Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio](https://www.quantisnow.com/insight/vyome-granted-chinese-patent-strengthening-immuno-inflammation-portfolio-6621890) - 2026-05-29 12:42 UTC [SEC Form 8-K] [Vyome Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/vyome-holdings-inc-filed-sec-form-8-k-results-of-operations-6578507) - 2026-05-12 20:03 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Vyome Holdings Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-vyome-holdings-inc-6547794) - 2026-04-29 20:16 UTC [SEC Form 8-K] [Vyome Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/vyome-holdings-inc-filed-sec-form-8-k-amendments-to-articles-6521441) - 2026-04-22 12:00 UTC [Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026](https://www.quantisnow.com/insight/vyome-presents-transformational-vt-1953-phase-2-clinical-study-data-at-6509531) - 2026-04-06 12:00 UTC [Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026](https://www.quantisnow.com/insight/vyome-to-present-compelling-phase-2-clinical-data-on-vt-1953-6488698) - 2026-03-31 10:03 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Vyome Holdings Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-vyome-holdings-inc-6477656) - 2026-03-26 12:00 UTC [Earnings] [Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase](https://www.quantisnow.com/insight/vyome-reports-transformational-2025-results-company-well-positioned-for-breakout-6470002) - 2026-03-20 20:56 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Vyome Holdings Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-vyome-holdings-inc-6463578) - 2026-03-18 10:38 UTC [SEC Form 10-K] [SEC Form 10-K filed by Vyome Holdings Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-vyome-holdings-inc-6454645) - 2026-02-25 21:15 UTC [SEC Form 8-K] [Vyome Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/vyome-holdings-inc-filed-sec-form-8-k-entry-into-a-6413176) - 2026-02-24 13:00 UTC [Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company](https://www.quantisnow.com/insight/livechain-completes-acquisition-of-senior-secured-debt-of-humanyze-an-6408918) - 2026-02-13 02:16 UTC [SEC Form 8-K] [Vyome Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/vyome-holdings-inc-filed-sec-form-8-k-regulation-fd-disclosure-6390906) - 2026-02-11 12:00 UTC [Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months](https://www.quantisnow.com/insight/vyome-files-for-vt-1953-orphan-drug-status-furthers-strategic-focus-6385539) - 2026-02-02 12:00 UTC [Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results](https://www.quantisnow.com/insight/vyome-successfully-capitalizes-all-vt-1953-funding-requirements-for-initial-phase-6368867) - 2026-01-28 14:00 UTC [SEC Form 8-K] [Vyome Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/vyome-holdings-inc-filed-sec-form-8-k-regulation-fd-disclosure-6363544) - 2026-01-27 13:00 UTC [Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study](https://www.quantisnow.com/insight/independent-analyst-values-vyomes-vt-1953-at-usd-1-billion-upon-6361549) - 2025-12-23 21:10 UTC [SEC Form 8-K] [Vyome Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits](https://www.quantisnow.com/insight/vyome-holdings-inc-filed-sec-form-8-k-entry-into-a-6326754) - 2025-12-22 13:00 UTC [Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company](https://www.quantisnow.com/insight/vyome-subsidiary-livechain-lich-to-acquire-senior-secured-note-in-6324762) - 2025-12-08 13:00 UTC [Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval](https://www.quantisnow.com/insight/vyome-reports-positive-final-phase-2-results-for-vt-1953-plans-6306220) - 2025-11-26 21:05 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Vyome Holdings Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-vyome-holdings-inc-6295045) - 2025-11-25 12:00 UTC [Leadership Update] [Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program](https://www.quantisnow.com/insight/vyome-appoints-renowned-medical-oncologist-dr-aditya-bardia-as-senior-6292722) - 2025-11-19 22:21 UTC [SEC Form 8-K] [Vyome Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/vyome-holdings-inc-filed-sec-form-8-k-results-of-operations-6287478) - 2025-11-19 21:10 UTC [SEC Form 4] [SEC Form 4 filed by Director Pomichter Stanley D Iii](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-pomichter-stanley-d-iii-6286960) - 2025-11-19 21:05 UTC [SEC Form 3] [SEC Form 3 filed by new insider Pomichter Stanley D Iii](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-pomichter-stanley-d-6286873) - 2025-11-18 23:45 UTC [SEC Form 4] [Director Jolly Mohanjit was granted 454,456 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-jolly-mohanjit-was-granted-454456-shares-sec-form-4-6285827) - 2025-11-18 23:44 UTC [SEC Form 3] [SEC Form 3 filed by new insider Jolly Mohanjit](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-jolly-mohanjit-6285825) - 2025-11-18 12:00 UTC [Earnings] [Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing](https://www.quantisnow.com/insight/vyome-holdings-announces-transformational-first-quarter-following-nasdaq-listing-6283897) - 2025-11-18 02:11 UTC [SEC Form 4] [SEC Form 4 filed by Director Tincoff John M. Iii](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-tincoff-john-m-iii-6283693) - 2025-11-18 00:36 UTC [SEC Form 4] [SEC Form 4 filed by Director Sengupta Shiladitya](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-sengupta-shiladitya-6283642) - 2025-11-18 00:35 UTC [SEC Form 3] [SEC Form 3 filed by new insider Sengupta Shiladitya](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-sengupta-shiladitya-6283641) ## More - Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/HIND - Earnings history: https://www.quantisnow.com/earnings/HIND - Dividend history: https://www.quantisnow.com/dividends/HIND - Insider transactions: https://www.quantisnow.com/insiders/HIND - Options chain: https://www.quantisnow.com/options/HIND - SEC 8-K filings only: https://www.quantisnow.com/company/HIND/8-k - RSS and alerts for HIND: https://www.quantisnow.com/docs/rss-feeds.md